BR112018073460A2 - terapias combinadas usando moduladores do receptor farnesoide x (fxr) - Google Patents

terapias combinadas usando moduladores do receptor farnesoide x (fxr)

Info

Publication number
BR112018073460A2
BR112018073460A2 BR112018073460A BR112018073460A BR112018073460A2 BR 112018073460 A2 BR112018073460 A2 BR 112018073460A2 BR 112018073460 A BR112018073460 A BR 112018073460A BR 112018073460 A BR112018073460 A BR 112018073460A BR 112018073460 A2 BR112018073460 A2 BR 112018073460A2
Authority
BR
Brazil
Prior art keywords
inhibitor
fxr
farnesoid
modulators
receptor
Prior art date
Application number
BR112018073460A
Other languages
English (en)
Portuguese (pt)
Inventor
Anthony Pratt Benjamin
Mohan Raju
Original Assignee
Akarna Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics Ltd filed Critical Akarna Therapeutics Ltd
Publication of BR112018073460A2 publication Critical patent/BR112018073460A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112018073460A 2016-05-25 2017-05-25 terapias combinadas usando moduladores do receptor farnesoide x (fxr) BR112018073460A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341487P 2016-05-25 2016-05-25
US201662341482P 2016-05-25 2016-05-25
PCT/US2017/034564 WO2017205684A1 (en) 2016-05-25 2017-05-25 Combination therapies with farnesoid x receptor (fxr) modulators

Publications (1)

Publication Number Publication Date
BR112018073460A2 true BR112018073460A2 (pt) 2019-07-09

Family

ID=60412964

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018073460A BR112018073460A2 (pt) 2016-05-25 2017-05-25 terapias combinadas usando moduladores do receptor farnesoide x (fxr)

Country Status (13)

Country Link
US (1) US20200397798A1 (cg-RX-API-DMAC10.html)
EP (1) EP3463373A4 (cg-RX-API-DMAC10.html)
JP (1) JP2019517478A (cg-RX-API-DMAC10.html)
KR (1) KR20190040936A (cg-RX-API-DMAC10.html)
CN (1) CN109843298A (cg-RX-API-DMAC10.html)
AU (1) AU2017270221A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018073460A2 (cg-RX-API-DMAC10.html)
CA (1) CA3025007A1 (cg-RX-API-DMAC10.html)
IL (1) IL263179A (cg-RX-API-DMAC10.html)
MX (1) MX2018014024A (cg-RX-API-DMAC10.html)
RU (1) RU2018145776A (cg-RX-API-DMAC10.html)
SG (2) SG11201810290WA (cg-RX-API-DMAC10.html)
WO (1) WO2017205684A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019025228A2 (pt) * 2017-06-02 2020-06-23 Akarna Therapeutics, Ltd. Compostos bicíclicos fundidos
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
JP2022514731A (ja) * 2018-08-14 2022-02-15 アヴォリント 原発性硬化性胆管炎の処置方法
WO2020081766A1 (en) * 2018-10-18 2020-04-23 Avolynt Use of sglt2 inhibitors to treat primary sclerosing cholangitis
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111825653A (zh) * 2019-04-19 2020-10-27 安道麦马克西姆有限公司 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
EP4061357A4 (en) * 2019-11-22 2024-01-10 Avolynt Use of sglt2 inhibitors to treat primary billiary cholangitis
IL296100A (en) * 2020-03-11 2022-11-01 Dong A St Co Ltd A medicinal preparation for the prevention or treatment of non-alcoholic steatohepatitis
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
US20220034871A1 (en) * 2020-07-31 2022-02-03 Daiichi Sankyo Company, Limited Methods for administering pexidartinib
PE20231096A1 (es) 2020-08-25 2023-07-18 Lilly Co Eli Polimorfos de un inhibidor de ssao
US20240319210A1 (en) * 2020-12-18 2024-09-26 Human Metabolomics Institute, Inc. Application of neonatal biliary atresia biomarker and detection method for same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009387A2 (en) * 2003-07-23 2005-02-03 X-Ceptor Therapeutics Inc. Azepine derivatives as pharmaceutical agents
ATE526318T1 (de) * 2005-12-19 2011-10-15 Glaxosmithkline Llc Farnesoid-x-rezeptor-agonisten
EP4137137A1 (en) * 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
AU2015314830B2 (en) * 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
CA2968434A1 (en) * 2014-11-21 2016-05-26 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
RU2021107054A (ru) * 2015-03-26 2021-03-31 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания

Also Published As

Publication number Publication date
MX2018014024A (es) 2019-08-29
AU2017270221A1 (en) 2018-12-20
EP3463373A4 (en) 2020-04-22
WO2017205684A1 (en) 2017-11-30
CN109843298A (zh) 2019-06-04
SG10202011660RA (en) 2020-12-30
JP2019517478A (ja) 2019-06-24
KR20190040936A (ko) 2019-04-19
EP3463373A1 (en) 2019-04-10
RU2018145776A3 (cg-RX-API-DMAC10.html) 2021-03-01
CA3025007A1 (en) 2017-11-30
RU2018145776A (ru) 2020-06-26
US20200397798A1 (en) 2020-12-24
IL263179A (en) 2018-12-31
SG11201810290WA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
MX2018014024A (es) Terapias de combinación con moduladores del receptor x farnesoide (fxr).
MX2024001205A (es) Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con compuestos antifibroticos para usarse en tratar enfermedades del higado graso.
ECSP20032650A (es) Análogos de incretina y sus usos
ECSP20032306A (es) Análogos de incretina y sus usos
MX390954B (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
PE20150200A1 (es) Formulacion de anticuerpos
BR112019001570A2 (pt) terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112016028961A8 (pt) fibras eletrotorcidas, seu método de preparação e seu uso, bem como composição, e kit
CL2020000974A1 (es) Tratamiento de la glomerulosclerosis focal y segmentaria con anatagonistas ccr2.
CR20170356A (es) Composiciones farmacéuticas para terapia combinada
BR112018067923A2 (pt) métodos de tratamento de cânceres usando antagonistas de ligação de eixo pd-1 e anticorpos anti-gpc3
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
BR112019009726A2 (pt) terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica
BR112017011780A2 (pt) inibidor de bromodomínio como composto auxiliar na imunoterapia para câncer
BR112018014661A2 (pt) composição e composição para uso
MX2018002000A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
BR112016004358A8 (pt) combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit
UY37800A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
MX2021000142A (es) Composiciones y metodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas.
MX2021002655A (es) Terapia de combinacion para el tratamiento de enfermedad hepatica.
BR112017011905A2 (pt) dispositivo intrauterino, sistema e método para tratamento de cavidade uterina
PE20150083A1 (es) Formulacion de ibuprofeno inyectable
BR112023003427A2 (pt) Terapia com antagonista de lag-3 para carcinoma hepatocelular
CO2019002245A2 (es) Combinación de agonistas de fxr

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements